<DOC>
	<DOCNO>NCT01591096</DOCNO>
	<brief_summary>Thrombolysis Pediatric Stroke ( TIPS ) five-year multi-center international safety dose-finding study intravenous ( IV ) tPA child acute ischemic stroke ( AIS ) determine maximal safe dose intravenous Tissue Plasminogen Activator ( IV-tPA ) among three dos ( 0.75 . 0.9 , 1.0 mg/kg ) child age 2-17 year within 4.5 hour onset acute AIS .</brief_summary>
	<brief_title>Thrombolysis Pediatric Stroke ( TIPS )</brief_title>
	<detailed_description>OBJECTIVES : 1 . To determine maximal safe dose intravenous ( IV ) tPA among three dos ( 0.75 . 0.9 , 1.0 mg/kg ) child age 2-17 year within 4.5 hour onset acute AIS . 2 . To determine pharmacokinetics tPA inhibitor , plasminogen activator inhibitor child . 3 . To measure 3-month neurological outcome child treat IV tPA . TRIAL DESIGN : Thrombolysis Pediatric Stroke ( TIPS ) five-year multi-center international safety dose-finding study intravenous ( IV ) tPA child acute AIS determine maximal safe dose intravenous ( IV ) tPA among three dos ( 0.75 . 0.9 , 1.0 mg/kg ) child age 2-17 year within 4.5 hour onset acute AIS . An adaptive dose find method apply escalate across three dose level within two age group : 2-10 year ( prepubertal ) 11-17 year . Dose escalate base safety ( absence excess toxicity ) least 3 child treat dose level . Intracranial hemorrhage follow stroke occur even absence thrombolytic therapy , risk increase use thrombolytic . Primary endpoint toxicity define SICH severe hemorrhage within 36 hour tPA administration , define follow : 1 . PH2 ( parenchymal hemorrhage within 36 hour tPA administration involve &gt; 30 % infarcted area ) , regardless whether associate clinical deterioration , OR , 2 . Any intracranial hemorrhage judge important cause neurological deterioration . Neurological deterioration guide minimum change 2 point PedNIHSS low PedNIHSS . At time PedNIHSS assessment , site PI co-PI review patient 's course care team ensure change neurologic status , include improvement since last assessment study team , capture , OR , 3 . Any hemorrhage result need transfusion , need discontinue study drug , surgical evacuation hemorrhage , death . TIPS determine pharmacokinetics tPA inhibitor , plasminogen activator inhibitor , include free tPA , PAI-1 , tPA antigen child receive IV tPA acute AIS . In addition , TIPS measure 3-month neurological outcome child treat IV tPA . TRIAL POPULATION : TIPS enroll maximum 18 child age 2-10 year maximum 18 child age 11-17 year within 4.5 hour onset acute AIS . On MRA CTA partial complete occlusion artery , consistent focal impairment arterial flow , correlate clinical deficit . TIPS STUDY INTERVENTION : Investigation label tPA obtain site Core Pharmacy commercially available recombinant tPA ( Genentech Activase® ) IV administration . The Bayesian method toxicity probability interval use select one follow three dose tier ( 0.75 , 0.9 , 1.0 mg/kg ) IV tPA . The dose escalation two age group ( 2-10 , 11-17 year ) perform independently . The maximum dose tier reach weight 90 kg .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>To eligible TIPS , patient must meet follow 1 . Age 2 17 year inclusive . 2 . Clinical presentation consist clearly define acute onset neurological deficit pattern consistent arterial territory ischemia . 3 . Clinically significant deficit define PedNIHSS score ≥ 6 ≤ 24 felt due acute stroke improving time initiation tPA administration 4 . Time symptom onset within 4.5 hour initiation treatment IV tPA . Time symptom onset define time patient last see awake neurological baseline . 5 . Radiological confirmation acute arterial ischemic stroke one two way : MRI confirmation , consist acute infarction restrict diffusion arterial territory consistent clinical syndrome plus MRA show partial complete occlusion intracranial artery correspond infarct location , OR , CT CT angiogram confirmation , consist normal head CT early hypodensity arterial territory consistent clinical syndrome plus CT angiogram show partial complete occlusion intracranial artery correspond infarct location . 6 . Baseline neuroimaging ( CT MRI ) evidence intracranial hemorrhage ( include HI1 , HI2 , PH1 PH2 ) . If head CT scan do , pretPA MRI must include Gradientrecalled ECHO ( GRE ) image Susceptibility Weighted Imaging ( SWI ) sequence . 7 . Children seizures follow onset stroke may include , long clinical picture consistent document arterial occlusion . 3.4.1.2.2 . Patients follow Exclusion Criteria eligible TIPS : Safety Related exclusion criterion : 1 . Patients time symptom onset unknown . 2 . Pregnancy 3 . Clinical presentation suggestive subarachnoid hemorrhage ( SAH ) , even head CT head MRI scan negative blood . 4 . Patient would decline blood transfusion indicate 5 . History prior intracranial hemorrhage 6 . Known cerebral arterial venous malformation , aneurysm , neoplasm 7 . Persistent Systolic Blood Pressure &gt; 15 % 95th percentile age sit supine 8 . Glucose &lt; 50 mg/dl ( 2.78 mmol/l ) &gt; 400 mg/dl ( 22.22 mmol/l ) 9 . Bleeding diathesis include platelet &lt; 100,000 , PT &gt; 15 sec ( INR &gt; 1.4 ) elevate PTT &gt; upper limit normal range . 10 . Clinical presentation consistent acute myocardial infarction ( MI ) postMI pericarditis require evaluation cardiology prior treatment 11 . Stroke , major head trauma , intracranial surgery within past 3 month 12 . Major surgery parenchymal biopsy within 10 day ( relative contraindication ) 13 . Gastrointestinal urinary bleeding within 21 day ( relative contraindication ) 14 . Arterial puncture noncompressible site lumbar puncture within 7 day ( relative contraindication ) . Patients cardiac catheterization via compressible artery exclude . 15 . Patient malignancy within 1 month completion treatment cancer 16 . Patients underlie significant bleeding disorder . Patients mild platelet dysfunction , mild von Willebrand Disease mild bleed disorder exclude . Stroke related exclusion : 1 . Mild deficit ( PedNIHSS &lt; 6 ) start tPA infusion 2 . Severe deficit suggest large territory stroke , pretPA PedNIHSS &gt; 25 , regardless infarct volume see neuroimaging 3 . Stroke suspect due subacute bacterial endocarditis , moyamoya , sickle cell disease , meningitis , bone marrow , air fat embolism 4 . Previously diagnose primary angiitis central nervous system ( PACNS ) secondary CNS vasculitis . Focal cerebral arteriopathy ( FCA ) childhood contraindication . Neuroimaging related exclusion : 1 . Intracranial hemorrhage ( HI1 , HI2 , PH1 PH2 ) pretreatment head MRI head CT 2 . Intracranial dissection ( defined distal opthalmic artery ) 3 . Large infarct volume , define find acute infarct MRI involve 1/3 complete MCA territory involvement , regardless pretPA PedNIHSS score due increase risk ICH.78 , 79 Drug Related exclusion : 1 . Known allergy recombinant tissue plasminogen activator 2 . Patient anticoagulation therapy must INR ≤ 1.4 3 . Patient receive heparin within 4 hour must aPTT normal range 4 . LMWH within past 24 hour ( aPTT INR reflect LMWH effect )</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Stroke</keyword>
	<keyword>Childhood</keyword>
	<keyword>Thrombolysis</keyword>
</DOC>